

## LETTER TO THE EDITOR

## Ibrutinib has some activity in Richter's syndrome

*Blood Cancer Journal* (2015) 5, e277; doi:10.1038/bcj.2014.98; published online 30 January 2015

Richter's syndrome (RS), defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, is seen in about 2–10% of all CLL patients.<sup>1</sup> The prognosis of RS is extremely poor with a median survival of about 6 months,<sup>2</sup> although patients with clonally unrelated RS may have a better prognosis.<sup>1</sup> No randomized controlled trials exist to date regarding therapeutic strategies in these patients. Data from phase I/II single-arm studies testing various therapeutic strategies have shown limited survival benefit with significant toxicity.<sup>2–6</sup> Here, we present two cases of RS treated with a novel therapeutic agent, ibrutinib (Table 1).

Patient A was a 60-year-old male diagnosed with Rai stage IV CLL after evaluation of progressive lymphadenopathy. Fluorescence *in situ* hybridization (FISH) showed no deletion of ataxia telangiectasia mutated gene, chromosome 11q (ATM), chromosome 13q14.3, or p53. One month later, he developed rapidly progressive lymphadenopathy that upon biopsy revealed clonally related, activated B-cell type (ABC) diffuse large B-cell lymphoma (DLBCL) with a proliferating index Ki-67 of 50% consistent with RS. He was treated with cycles of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP), rituximab/ifosfamide/carboplatin/etoposide (RICE) and rituximab/gemcitabine/oxaliplatin; however, his disease was refractory to these conventional therapeutic regimens. He was not a candidate for allogeneic hematopoietic stem cell transplantation due to a lack of insurance. Thus, the patient was started on ibrutinib. One month later, computed tomography (CT) scan revealed 70% regression of his disease, which improved at 3 months to 90% regression of disease.

Patient B was a 59-year-old male who was diagnosed with Rai stage III CLL after evaluation of anemia with lymphocytosis.

He was observed for 8 years until he developed progressive lymphocytosis that required treatment of his CLL with bendamustine/rituximab and fludarabine/cyclophosphamide/rituximab. FISH showed trisomy 12 in 34% of nuclei and deletion of p53 in 40% of nuclei, but deletion of ATM and 13q14.3 were not detected. Subsequently, he developed fever, night sweats and rapidly progressing lymphadenopathy for which biopsy of his right neck lymphadenopathy revealed clonally related, ABC DLBCL with a proliferating index Ki-67 of 90% consistent with RS. He was treated with multiple cycles of R-CHOP and RICE. He had poor prognostic features, given his p53 deletion, high LDH level and bulky disease with lung nodular disease. His lymphoma was refractory to these conventional therapeutic regimens, and he was not a candidate for allogeneic hematopoietic stem cell transplantation due to a lack of insurance. Thus, he was started on ibrutinib. CT scan 2 months later showed 100% progression of his neck adenopathy. Ibrutinib was stopped after 3 months due to refractory disease.

Recent studies have shown that ibrutinib, a potent inhibitor of Bruton's tyrosine kinase receptor, is a viable therapeutic option in cases of relapsed/refractory CLL.<sup>7,8</sup> It remains unclear if this drug is effective against patients with RS as well. In an earlier phase Ib/II study on combination of ibrutinib with ofatumumab, a partial response was seen in two out of three patients with RS.<sup>9</sup> It was not clear that whether these patients had different genetic profiles. In our case, both patients had ABC type DLBCL, which has been shown to have a better response to ibrutinib as compared with germinal center B-cell type DLBCL.<sup>10</sup> However, patient A had an excellent response whereas patient B was refractory to ibrutinib therapy. In contrast to patient A, patient B had high-risk mutations (deletion of p53 and trisomy of chromosome 12) and a high-proliferation index (Ki-67 of 90%) suggesting a poor prognosis. This may suggest that ibrutinib is beneficial in a select group of patients with distinct genetic profiles. Our experience with these patients adds to a growing hypothesis that ibrutinib may be a viable therapeutic option in CLL patients with RS.

**Table 1.** Summary of previously published phase I/II single-arm studies regarding various chemotherapeutic options for the treatment of Richter's syndrome

Author, year	Number of patients	Therapy type and duration	Response rate and toxicity
Dabaja <i>et al.</i> , <sup>2</sup>	N = 29, all with RS	Hyper CVXD every 3–4 week intervals for a maximum of six cycles	ORR of 41%, grade IV granulocytopenia occurred in all cycles, 14% died during the first cycle of therapy
Tsimberidou <i>et al.</i> , <sup>4</sup>	N = 22 (16 RS, 3 refractory PLL, 1 refractory NHL)	FACPGM every 4 weeks and continued as tolerated	CRR of 5%, grade III/IV hematologic toxicities in 66–90%, 18% died after the first cycle of therapy <sup>a</sup>
Tsimberidou <i>et al.</i> , <sup>3</sup>	N = 49 (30 RS, 19 refractory CLL)	Hyper CVXD+R and GM-CSF alternating with methotrexate, cytarabine+R and GM-CSF for upto 6 cycles	ORR of 41%, grade IV neutropenia seen during all cycles, 18% died during the first cycle therapy <sup>a</sup>
Tsimberidou <i>et al.</i> , <sup>5</sup>	N = 50 (20 RS, 30 refractory CLL)	OFAR every 4 weeks for a maximum of six cycles	ORR of 50% in RS, grade III/IV hematologic toxicities seen in 21–100%
Tsimberidou <i>et al.</i> , <sup>6</sup>	N = 102, (35 RS, 67 relapsed/refractory CLL)	OFAR2 every 4 weeks for a total of 6 weeks	ORR of 42.9% in RS, grade III/IV hematologic toxicities seen in 49–79%

Abbreviations: CLL, chronic lymphocytic leukemia; CRR, complete remission rate; FACPGM, fludarabine, cytarabine, cyclophosphamide, cisplatin, granulocyte macrophage colony stimulating factor; hyper CVXD, fractionated cyclophosphamide, vincristine, liposomal daunorubicin and dexamethasone; NHL, non-Hodgkins lymphoma; OFAR, oxaliplatin, fludarabine, cytarabine, rituximab and pegfilgrastim; OFAR2, similar to OFAR1 with some dosing modifications; ORR, overall response rate; PLL, pro-lymphocytic leukemia; RS, Richter's syndrome. <sup>a</sup>Response rate of RS patients not separately available.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

MGM compiled the patients treated; all authors wrote the manuscript and contributed to revisions.

S Giri<sup>1</sup>, A Hahn<sup>1</sup>, G Yaghmour<sup>2</sup> and MG Martin<sup>2</sup>

<sup>1</sup>Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA and

<sup>2</sup>Department of Hematology/Oncology, The West Clinic, Memphis, TN, USA

E-mail: mmartin@westclinic.com

**REFERENCES**

- 1 Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. *Blood* 2014; **123**: 1647–1657.
- 2 Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M *et al*. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoX-ome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. *Leuk Lymphoma* 2001; **42**: 329–337.
- 3 Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G *et al*. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. *Cancer* 2003; **97**: 1711–1720.
- 4 Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM *et al*. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. *Leuk Lymphoma* 2002; **43**: 767–772.
- 5 Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S *et al*. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 2008; **26**: 196–203.
- 6 Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ *et al*. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. *Clin Lymphoma Myeloma Leuk* 2013; **13**: 568–574.
- 7 Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM *et al*. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *N Engl J Med* 2014; **371**: 213–223.
- 8 Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA *et al*. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med* 2013; **369**: 32–42.
- 9 Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, AMaddocks KJ, Blum KA *et al*. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. *J Clin Oncol* 2012; **30**. suppl; abstract 6508.
- 10 Gerecitano JF, Goy A, De Vos S, Kenkre VP, Barr PM, Blum KA *et al*. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory *De Novo* Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. *American Society of Hematology*; 8–11 December 2012; Atlanta, GA, USA. 2012.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>